Table of Contents
1
UI - 11825654
AU - Tseng WW; Liu CD
TI -
Peptide YY and cancer: current findings and potential clinical
applications.
SO - Peptides 2002 Feb;23(2):389-95
AD - Northwestern University Medical School, Chicago, Illinois 60611, USA.
Peptide YY (PYY) is a naturally occurring gut hormone with mostly
inhibitory actions on multiple tissue targets. PYY has been identified
in several carcinoid tumors and a decreased expression of PYY may be
relevant to the development and progression of colon adenocarcinoma.
Treatment with PYY decreases growth in pancreatic and breast tumors,
most likely through a reduction in intracellular cAMP. In cancer
patients, PYY may also improve malnutrition that results from iatrogenic
causes or cachexia associated with advanced disease. PYY plays a
significant role in multiple aspects of cancer from regulation of cell
growth to potential therapeutic applications.
2
UI - 11884049
AU - Kawahara M; Kammori M; Kanauchi H; Noguchi C; Kuramoto S; Kaminishi M;
TI -
Endo H; Takubo K
Immunohistochemical prognostic indicators of gastrointestinal carcinoid
tumours.
SO - Eur J Surg Oncol 2002 Mar;28(2):140-6
AD - Department of Gastroenterological Surgery, University of Tokyo, Tokyo,
Japan. KAWAHARAM-DIS@h.u-tokyo.ac.jp
AIMS: The aim of this study was to determine whether expression of the
oncoproteins p21, p53, E-cadherin (EC), cyclin D1, bcl-2 and Rb and the
proliferation marker Ki-67 is predictive of malignant behaviour in
gastrointestinal carcinoid tumours. METHODS: Immunohistochemical (IHC)
staining was performed on carcinoid tumours from 41 patients (31 rectal,
eight gastrointestinal, two appendiceal lesions). The six tumours that
had invaded deeply into the muscularis propria or beyond, had
metastasized to regional lymph nodes or had metastasized to a distant
site were classified as the malignant group, and the other 35 tumours
formed the benign group. IHC expression was compared between the two
groups, and the prognostic value of each marker was assessed. RESULTS:
Of the six tumours in the malignant group, 66.7% were p21 positive, 0%
were p53 positive, 33.3% were EC positive, 100% were cyclin D1 positive,
33.3% were Rb positive, 16.7% were bcl-2 positive and 50% were Ki-67
positive. Of the 35 tumours in the benign group, 17.1% were p21
positive, 0% were p53 positive, 100% were EC positive, 94.3% were cyclin
D1 positive, 8.6% were Rb positive, 17.1% were bcl-2 positive and 0%
were Ki-67 positive. CONCLUSIONS: These data show that p53, cyclin D1,
Rb, bcl-2 and Ki-67 staining does not correlate with malignant behaviour
but that overexpression of p21 (P=0.02) and reduced staining of EC
(P=0.005) do correlate with malignant behaviour. These two parameters
may therefore be useful as prognostic indicators for gastrointestinal
carcinoid tumours. Copyright Harcourt Publishers Limited.
3
UI - 11782714
AU - Bresciani M; Camera L; Soscia E; Imbriaco M; Selva G; Salvatore M
TI -
[CT in findings intestinal carcinoids]
SO - Minerva Endocrinol 2001 Dec;26(4):269-72
AD - Dipartimento di Scienze Biomorfologiche e Funzionali Sezione di
Diagnostica per Immagini e Radioterapia, Universita degli Studi Federico
II, Naples, Italy.
CT findings in intestinal carcinoids are various. While recognition of
the primary tumour is a rare event, the contribution of CT in evaluating
patients with suspected intestinal carcinoid is relevant, both for
loco-regional staging and during long-term follow-up. Moreover, in the
relatively frequent cases with an aspecific clinical onset, CT may be
findings useful to direct diagnosis.
4
UI - 11965607
AU - Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
TI -
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic
malignancies.
SO - Semin Nucl Med 2002 Apr;32(2):123-32
AD - Louisiana State University Medical Center, Department of Medicine, the
Louisiana State University Health Sciences Center (LSUHSC), Stanley S.
Scott Cancer Center, New Orleans, LA 70112, USA.
Somatostatin and its analogues bind to somatostatin receptors (sst) 1
through 5 that are overexpressed in neuroendocrine neoplasms such as
gastroenteropancreatic (GEP) malignancies. After ligand-receptor
binding, a fraction of the ligand-receptor complexes internalize. This
internalization process is an effective means of delivering cytotoxic
radiolabeled somatostatin analogues, especially those emitting
short-range decay particles such as Auger electrons, to the neoplastic
cell nucleus. Indium-111-pentetreotide, an sst 2 preferring somatostatin
analogue with gamma and Auger electron decay characteristics, is
commonly used for the scintigraphic evaluation and management of
neuroendocrine cancer patients. This clinical trial was performed to
determine the effectiveness and tolerability of therapeutic doses of
(111)In-pentetreotide in patients with GEP tumors. GEP tumor patients
who had failed all forms of conventional therapy, with worsening of
tumor-related signs and symptoms and/or radiographically documented
progressive disease, an expected survival less than 6 months, and sst
positivity as determined by the uptake on a 6.0 mCi
(111)In-pentetreotide scan (OctreoScan; Mallinckrodt Medical, Inc, St.
Louis, MO), were treated with at least 2 monthly 180-mCi intravenous
injections of (111)In-pentetreotide. Baseline clinical assessments,
serum chemistries, and plasma pancreastatin levels were measured and
and 3 pancreatic islet cells) patients were accrued, with 26 patients
evaluable for clinical and radiographic responses, 21 patients evaluable
for biochemical assessments, and 27 patients evaluable for survival
analysis and safety. Toxicity was evaluated by using standard National
Cancer Institute (NCI) Common Toxicity Criteria guidelines. Clinical
benefit occurred in 16 (62%) patients. Pancreastatin levels decreased by
50% or more in 81% of the patients. Objective partial radiographic
responses occurred in 2 (8%) patients, and significant tumor necrosis
(defined by 20 Hounsfield units or greater decrease from baseline)
developed in 7 (27%) patients. The following transient Grades 3/4 NCI
Common Toxicity Criteria side effects were observed, respectively:
leukocyte: 1/1; platelets: 0/2; hemoglobin: 3/0; bilirubin: 1/3;
creatinine: 1/0; neurologic: 1/0. Myeloproliferative disease and/or
myelodysplastic syndrome have not been observed in the 6 patients
followed-up for 48+ months. The median survival was 18 months (range,
3-54+ mo). Two doses (180 mCi) of (111)In-pentetreotide are safe,
well-tolerated, and improve symptoms in 62% of patients, decrease
hormonal markers in 81% of patients, decrease Hounsfield units on
computed tomography (CT) scans in 27% of patients, with 8% partial
radiographic responses and increased expected survival in GEP cancer
patients with somatostatin receptor-expressing tumors. The maximal
tolerated dose of (111)In-pentetreotide and the optimal dosing schedules
remain under investigation. Copyright 2002, Elsevier Science.
5
UI - 10782147
AU - Maiorana A; Fante R; Maria Cesinaro A; Adriana Fano R
TI -
Synchronous occurrence of epithelial and stromal tumors in the stomach:
a report of 6 cases.
SO - Arch Pathol Lab Med 2000 May;124(5):682-6
AD - Sezione di Anatomia Patologica, Dipartimento di Scienze Morfologiche e
Medico-Legali, University of Modena, Modena, Italy.
OBJECTIVE: The synchronous development of epithelial and stromal tumors
in the stomach has been reported rarely in the literature. A series of 6
such cases is described in this article. METHODS: Clinical and
pathologic data were recorded and the literature was reviewed. RESULTS:
Five cases featured the simultaneous occurrence of stromal tumors (1
benign, 3 borderline, 1 malignant) and adenocarcinomas, whereas the
stromal tumor in the sixth case was found in association with a
carcinoid. No collision tumors were observed. In 2 cases, tumors arose
from the same site and were closely juxtaposed, but in 4 patients they
developed from different areas of the stomach. A preoperative histologic
diagnosis of both tumors was not achieved in any case. Two patients
harbored occult infiltrative epithelial lesions (1 diffuse-type
adenocarcinoma, 1 carcinoid), which were detected only at pathologic
examination of the gastric mucosa adjacent to the stromal tumor.
CONCLUSIONS: The simultaneous occurrence of epithelial and stromal
tumors in the stomach can be less rare than usually expected.
Coincidence alone could account for such an association, particularly in
areas with high incidence rates of gastric cancer. The hypothesis that a
single carcinogenic agent might interact with two neighboring tissues in
the stomach inducing the development of tumors of different histotype
cannot be theoretically discarded.
6
UI - 11757291
AU - Petrova MV; Voskresenskii SV; Krasnova TE
TI -
[Changes in mechanical properties of the lungs in thoracic surgery in
cancer patients]
SO - Anesteziol Reanimatol 2001 Sep-Oct;(5):16-9
Mechanical characteristics of the lungs and time course of their changes
at various stages of thoracal surgery were studied in 119 cancer
patients. Lung compliance significantly decreased during transfer of the
patients into lateral position. The ranges of normal values of lung
compliance and aerodynamic resistance at the stage of one-lung
ventilation were determined. The studies confirmed the necessity of
intraoperative spirometry in the complex of thoracal operation
monitoring.
7
UI - 11981015
AU - Schwarz RE; Fuller RA; Chu P
TI -
Unusual presentations of uncommon tumors: case 2. Gastric carcinoid
metastatic to the liver.
SO - J Clin Oncol 2002 May 1;20(9):2403-4
AD - City of Hope National Medical Center, Duarte, CA, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home